Research ArticleConference Proceedings

Exacerbations of COPD

Brian W Carlin
Respiratory Care July 2023, 68 (7) 961-972; DOI: https://doi.org/10.4187/respcare.10782

REFERENCES

  1. 1.↵
    1. Lange P,
    2. Celli B,
    3. Agusti A,
    4. Boje G,
    5. Jensen M,
    6. Divo R,
    7. et al
    . Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015;373(2):111-122.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Coler-Cataluna JJ,
    2. Martinez-Garcia MA,
    3. Sanchez RP,
    4. Salcedo E,
    5. Navarro M,
    6. Ochando R
    . Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Rodriguez-Roisin R
    . Toward a consensus definition for COPD exacerbations. Chest 2000;117(5):398S-401S.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Anthonisen NR,
    2. Mandreda J,
    3. Warren CP,
    4. Hershfield ES,
    5. Harding GK,
    6. Nelson NA
    . Antibiotic treatment in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106(2):196-204.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Celli BR,
    2. Fabbri LM,
    3. Aaron SD,
    4. Agusti A,
    5. Brook R,
    6. Criner GJ,
    7. et al
    . An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2021;204(11):1251-1258.
    OpenUrl
  6. 6.↵
    1. Ritchie AL,
    2. Wedzicha JA
    . Definition, causes, pathogenesis, and consequences of chronic obstructive disease exacerbations. Clin Chest Med 2020;41(3):421-438.
    OpenUrl
  7. 7.↵
    1. Kunadharaju R,
    2. Sethi S
    . Treatment of acute exacerbations in chronic obstructive pulmonary disease. Clin Chest Med 2020;41(3):439-451.
    OpenUrl
  8. 8.↵
    1. Hurst JR,
    2. Vestbo J,
    3. Anzueto A,
    4. Locantore N,
    5. Mullerova H,
    6. Tal-Singer R,
    7. et al
    ; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-1138.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Wells JM,
    2. Washko GR,
    3. Han MK,
    4. Abbas N,
    5. Nath H,
    6. Mamary AJ,
    7. et al
    . Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012;367(10):913-921.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Stolz D,
    2. Kostikas K,
    3. Loefroth E,
    4. Fogel R,
    5. Gutzwiller FS,
    6. Conti V,
    7. et al
    . Differences in COPD exacerbation risk between men and women. CHEST 2019;156(4):674-684.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Kim V,
    2. Zhao H,
    3. Regan E,
    4. Han MK,
    5. Make BJ,
    6. Crapo JD,
    7. et al
    ; and COPDGene Investigators. The St. George’s Respiratory Questionnaire definition of chronic bronchitis may be a better predictor of COPD exacerbations compared with the classic definition. Chest 2019;156(4):685-695.
    OpenUrlPubMed
  12. 12.↵
    1. Thomashow B,
    2. Stiegler M,
    3. Criner GJ,
    4. Dransfield MT,
    5. Halpin DMG,
    6. Han ML,
    7. et al
    . Higher COPD Assessment Test score associated with greater exacerbations risk: a post hoc analysis of the IMPACT trial. Chronic Obstr Pulm Dis 2022;9(1):68-79.
    OpenUrl
  13. 13.↵
    1. Yawn BP,
    2. Han ML,
    3. Make BM,
    4. Mannino D,
    5. Brown RW,
    6. Meldrum C,
    7. et al
    . Protocol summary of the COPD assessment in primary care to identify undiagnosed respiratory disease and exacerbation risk (CAPTURE). Validation in primary care study. Chron Obstr Pulm Dis 2021;8(1):60-75.
    OpenUrl
  14. 14.↵
    1. Singh D,
    2. Edwards L,
    3. Tal-Singer R,
    4. Rennard S
    . Sputum neutrophils as a biomarker for COPD: findings from the ECLIPSE study. Respir Res 2010;11(1):77.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Singh D,
    2. Agusti A,
    3. Martinez FJ,
    4. Papi A,
    5. Pavord ID,
    6. Wedzicha JA,
    7. et al
    . Blood eosinophils and chronic obstructive pulmonary disease. A global initiative for obstructive lung disease since committee 2022 review. Am J Respir Crit Care Med 2022;206(1):17-24.
    OpenUrlPubMed
  16. 16.↵
    1. Esther CR,
    2. O’Neal WK,
    3. Anderson WH,
    4. Kesimer M,
    5. Ceppe A,
    6. Doerschuk CM,
    7. et al
    . Identification of sputum biomarkers of pulmonary exacerbations in COPD. Chest 2022;161(5):1239-1249.
    OpenUrl
  17. 17.↵
    1. Di J,
    2. Li X,
    3. Xie Y,
    4. Yang S,
    5. Yu X
    . Procalcitonin-guided antibiotic therapy in AECOPD patients: overview of systematic reviews. Clin Respir J 2021;15(6):579-594.
    OpenUrl
  18. 18.↵
    1. Renaud C,
    2. Kollef M
    . Classical and molecular techniques to diagnose HAP/VAP. Semin Respir Crit Care 2022;43(2):219-228.
    OpenUrl
  19. 19.↵
    1. Mathioudakis AG,
    2. Janssens W,
    3. Sivapalan P,
    4. Singanayagam A,
    5. Dransfield MT,
    6. Jensen J-US,
    7. Vestbo J
    . Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax 2020;75(6):520-527.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Soler-Cataluña JJ,
    2. Piñera P,
    3. Trigueros JA,
    4. Calle M,
    5. Casanova C,
    6. Cosío BG,
    7. et al
    . Spanish COPD guidelines (GesRPOC) 2021 update. Diagnosis and treatment of COPD exacerbation syndrome. Translated article. Arch Bronco 2022;58(2):T159-T170.
    OpenUrl
  21. 21.↵
    1. Wedzicha JA,
    2. Miravitlles M,
    3. Hurst JR,
    4. Calverley PMA,
    5. Albert RK,
    6. Anzueto A,
    7. et al
    . Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;49(3):1600791.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Dobler CC,
    2. Morrow AS,
    3. Beuschel B,
    4. Farah MH,
    5. Majzoub AM,
    6. Wilson ME,
    7. et al
    . Pharmacologic therapies in patients with exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2020;172(6):413-422.
    OpenUrl
  23. 23.↵
    1. Lee RA,
    2. Centor RM,
    3. Humphrey LL,
    4. Jokela JA,
    5. Andrews R,
    6. Qaseem A
    . Appropriate use of short-term course antibiotics in common infection: best practice advice from the American College of Physicians. Ann Intern Med 2021;174(6):822-827.
    OpenUrlPubMed
  24. 24.↵
    Global Initiative for Obstructive Lung Disease. Available at: https//www.goldcopd.org. Accessed February 14, 2023.
  25. 25.↵
    1. vanGeffen WH,
    2. Douma WR,
    3. Slebos DJ,
    4. Kerstjens HAM
    . Bronchodilators delivered by nebulizer pMDI with space or DPI for exacerbations of COPD. Cochrane Database Syst Rev 2016;8:CD011826.
    OpenUrlPubMed
  26. 26.↵
    1. McCrory DC,
    2. Brown CD
    . Anti-cholinergic bronchodilators versus beta-2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2001CD003900.
  27. 27.↵
    1. Aaron SD,
    2. Vandemheen KL,
    3. Hebert P,
    4. Dales R,
    5. Stiell IG,
    6. Ahuja J
    . Out-patient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;34(26):2618-2625.
    OpenUrl
  28. 28.↵
    1. Leuppi JS,
    2. Schuetz P,
    3. Bingisser R,
    4. Bodmer M,
    5. Briel M,
    6. Drescher T,
    7. et al
    . Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013;309(21):2223-2231.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Sivapalan P,
    2. Ingebrigtsen TS,
    3. Rasmussen DB,
    4. Sorensen R,
    5. Rasmussen CM,
    6. Jensen CB,
    7. et al
    . COPD exacerbations: the impact of long versus short course of oral steroids on mortality and pneumonia: nationwide data on 67,000 patients followed for 12 months. BMJ Open Resp Res 2019;6(1):e000407.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Ram FSF,
    2. Rodriguez-Roisin R,
    3. Granados-Navarrete A,
    4. Garcia-Aymerich J,
    5. Barnes NC
    . Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Syst Rev 2006;2: CD004403.
  31. 31.↵
    1. Llor C,
    2. Moragas A,
    3. Miravitlles M,
    4. Mesquita P,
    5. Cordoba G
    . Are short courses of antibiotic therapy as effective as standard course for COPD exacerbations? A systematic review and meta-analysis. Pulm Pharmacol Ther 2022;72:102111.
    OpenUrl
  32. 32.↵
    1. Jacobs DM,
    2. Pandit U,
    3. Sethi S
    . Acute exacerbations in chronic obstructive pulmonary disease: should we use antibiotics and if so, which ones? Curr Opin Infect Dis 2019;32(2):143-151.
    OpenUrl
  33. 33.↵
    1. Dobler CC,
    2. Morrow AS,
    3. Farah MH,
    4. Beuschel B,
    5. Majzoub AM,
    6. Wilson ME,
    7. et al
    . Nonpharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis. Mayo Clin Proc 2020;95(6):1169-1183.
    OpenUrl
  34. 34.↵
    1. Waeijen-Smit K,
    2. Houben-Wilke S,
    3. DiGiandomenico A,
    4. Gehrmann U,
    5. Franssen FME
    . Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med 2021;16(3):559-569.
    OpenUrl
  35. 35.↵
    1. Howcroft M,
    2. Walters EH,
    3. Wood-Baker R,
    4. Walters JAE
    . Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. Cochrane Database for Syst Rev 2016;12:CD005074.
    OpenUrl
  36. 36.↵
    1. Ries AL,
    2. Prewitt LM,
    3. Johnson JJ
    . Skin color and ear oximetry. Chest 1989;96(2):287-290.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Gottlieb ER,
    2. Ziegler J,
    3. Morley K,
    4. Rush B,
    5. Celi LA
    . Assessment of racial and ethnic differences in oxygen supplementation among patients in the intensive care unit. JAMA Intern Med 2022;182(8):849-858.
    OpenUrl
  38. 38.↵
    1. Kallstrom TJ
    . AARC clinical practice guideline: oxygen therapy for adults in the acute care facility. Respir Care 2002;47(6):717-720.
    OpenUrlPubMed
  39. 39.↵
    1. Osadnik CR,
    2. Tee VS,
    3. Carson-Chahhoud V,
    4. Picot J,
    5. Wedzicha JA,
    6. Smith BJ
    . Noninvasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017;7(7):CD004104.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Cortegiani A,
    2. Longhini F,
    3. Madotto F,
    4. Groff P,
    5. Scala R,
    6. Crimi C,
    7. et al
    ; the H. F.-AECOPD study investigators. High-flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multi-center non-inferiority randomized trial. Crit Care 2020;24(1):692-695.
    OpenUrlPubMed
  41. 41.
    1. Feng Z,
    2. Zhang L,
    3. Yu H,
    4. Su X,
    5. Shuai T,
    6. Zhu L,
    7. et al
    . High-flow nasal cannula oxygen therapy versus noninvasive ventilation for AECOPD patients after extubation: a systematic review and meta-analysis of randomized controlled trials. COPD 2022;17:1987-1999.
    OpenUrl
  42. 42.↵
    1. Oczkowski S,
    2. Ergan B,
    3. Bos L,
    4. Chatwin M,
    5. Ferrer M,
    6. Gregoretti C,
    7. et al
    . ERS clinical practice guideline: high-flow nasal cannula in acute respiratory failure. Eur Respir J 2022;59(4):2101574.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Criner GJ,
    2. Bourbeau J,
    3. Diekemper RL,
    4. Ouellette DR,
    5. Goodridge D,
    6. Hernandez P,
    7. et al
    . Executive summary. Prevention of acute exacerbation of COPD: American College of Chest Physician and Canadian Thoracic Society Guideline. Chest 2015;147(4):883-893.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Wedzicha JA,
    2. Calverley PMA,
    3. Albert RK,
    4. Anzueto A,
    5. Criner GH,
    6. Hurst JR,
    7. et al
    . Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;50(3):1602265.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Bourbeau J,
    2. Bhutani M,
    3. Hernandez P,
    4. Aaron SD,
    5. Balter M,
    6. Beauchesne MF,
    7. et al
    . Canadian Thoracic Society Clinical Practice guideline on pharmacotherapy in patients with COPD-2019 update of evidence. Can J Respir Crit Care 2019;3(4):21-232.
    OpenUrl
  46. 46.↵
    1. Cookson W,
    2. Moffatt M,
    3. Rapeport G,
    4. Quint J
    . A pandemic lesion for global lung disease: exacerbations are preventable. Am J Respir Crit Care Med 2022;205(11):1271-1280.
    OpenUrl
  47. 47.↵
    1. So JY,
    2. O’Hara NN,
    3. Kenaa B,
    4. Williams JG,
    5. deBorja CL,
    6. Slejko JF,
    7. et al
    . Population decline in COPD admissions during the COVID-19 pandemic associated with lower burden of community respiratory viral infections. Am J Med 2021;134(10):1252-1259.e3.
    OpenUrl
  48. 48.↵
    Centers for Disease Control. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html. Accessed February 14, 2023.
  49. 49.↵
    1. Vestbo J,
    2. Anderson JA,
    3. Brook RD,
    4. Calverley PMA,
    5. Celli BR,
    6. Crim C,
    7. et al
    . Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomized clinical trial. Lancet 2016;387(10030):1817-1826.
    OpenUrlPubMed
  50. 50.↵
    1. Wedzicha JA,
    2. Banerji D,
    3. Chapman DK,
    4. Vestbo J,
    5. Roche N,
    6. Ayers RT,
    7. et al
    ; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone. N Engl J Med 2016;374(23):2222-2234.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Lipson DA,
    2. Barnhart F,
    3. Brealey N,
    4. Brooks J,
    5. Criner GJ,
    6. Day NC,
    7. et al
    . Once-daily single-inhaler triple therapy versus dual therapy in patients with COPD. N Engl J Med 2018;378(18):1671-1680.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Rabe KF,
    2. Martinez FJ,
    3. Ferguson GT,
    4. Wang C,
    5. Singh D,
    6. Wedzicha JA,
    7. et al
    . Triple therapy at two glucocorticoid doses in moderate-to-very severe COPD. N Engl J Med 2020;383(1):35-48.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Yun JH,
    2. Lamb A,
    3. Chase R,
    4. Singh D,
    5. Parker MM,
    6. Saferali A,
    7. et al
    . Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018;141(6):2037-2047.e10.
    OpenUrlCrossRef
  54. 54.↵
    1. Calverley PMA,
    2. Magnussen H,
    3. Miravitlles M,
    4. Wedzicha JA
    . Triple therapy in COPD. What we know and what we don’t. COPD 2017;14(6):648-662.
    OpenUrl
  55. 55.↵
    1. Martinez FJ,
    2. Calverley PMA,
    3. Goehring UM,
    4. Brose M,
    5. Fabbri LM,
    6. Rabe KF
    . Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multi-center randomized controlled trial. Lancet 2015;385(9971):857-866.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Albert RK,
    2. Connett J,
    3. Bailey WC,
    4. Casaburi R,
    5. Cooper JAD,
    6. Criner GJ,
    7. et al
    ; COPD Clinical Research Network. Azithromycin for preventions of exacerbations of COPD. N Engl J Med 2011;365(8):689-698.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Poole P,
    2. Chong J,
    3. Cates CJ
    . Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;7:CD001287.
    OpenUrl
  58. 58.↵
    1. Bauldoff GS,
    2. Carlin BW
    , AACVPR guidelines for pulmonary rehabilitation program, 5th edition. Champaign, Illinois: Human Kinetics; 2018.
  59. 59.↵
    1. Greening NJ,
    2. Williams JEA,
    3. Hussain SF,
    4. Harvey-Dunstan TC,
    5. Bankart MJ,
    6. Chaplin EJ,
    7. et al
    . An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomized controlled trial. BMJ 2014;349(jul08 5):g4315-g4315.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Ryrsø CK,
    2. Godtfredsen NS,
    3. Kofod LM,
    4. Lavesen M,
    5. Mogensen L,
    6. Tobberup R,
    7. et al
    . Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med 2018;18(1):154. doi:10.1186/s12890-018-0718-1.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Lindenauer PK,
    2. Stefan MS,
    3. Pekow PS,
    4. Mazor KM,
    5. Priya A,
    6. Spitzer KA,
    7. et al
    . Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among Medicare beneficiaries. JAMA 2020;323(18):1813-1823.
    OpenUrlPubMed
  62. 62.↵
    1. Cox NS,
    2. Oliveira CC,
    3. Lahham A,
    4. Holland AE
    . Pulmonary rehabilitation referral and participation are commonly influenced by environment, knowledge, and beliefs about consequences: a systematic review using the theoretical domains framework. J Physiother 2017;63(2):84-93.
    OpenUrlPubMed
  63. 63.↵
    1. Holland AE,
    2. Mahal A,
    3. Hill CJ,
    4. Lee AL,
    5. Burge AT,
    6. Cox NS,
    7. et al
    . Home-based rehabilitation for COPD using minimal resources: a randomized controlled equivalence trial. Thorax 2017;72(1):57-65.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Locke E,
    2. Young JP,
    3. Battaglia C,
    4. Simpson TL,
    5. Trivedi R,
    6. Simons C,
    7. et al
    . Care-seeking and delay of care curing COPD exacerbations. NPJ Prim Care Respir Med 2022;32:7.
    OpenUrl
  65. 65.↵
    1. Gillespie D,
    2. Francis N,
    3. Ahmed H,
    4. Hood K,
    5. Llor C,
    6. White P,
    7. et al
    . Associations with post-consultation health-status in primary care managed acute exacerbation of COPD. COPD 2022;17:383-394.
    OpenUrl
  66. 66.↵
    1. Bryant J,
    2. McDonald VM,
    3. Boyes A,
    4. Sanson-Fisher R,
    5. Paul C,
    6. Melville J
    . Improving medication adherence in COPD: a systematic review. Respir Res 2013;14(1):109.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Lopez-Campos JL,
    2. Gallego EQ,
    3. Hernandez LC
    . Status of and strategies for improving adherence to COPD treatment. COPD 2019;14:1503-1515.
    OpenUrl
  68. 68.↵
    1. Stone PW,
    2. Adamson A,
    3. Hurst JR,
    4. Roberts CM,
    5. Quint JK
    . Does pay-for-performance improve patient outcomes in acute exacerbations of COPD admissions. Thorax 2022;77(3):239-246.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Au DH,
    2. Collins MP,
    3. Berger DB,
    4. Carvalho PG,
    5. Nelson KM,
    6. Reinke LF,
    7. et al
    . Health system approach to improve chronic obstructive pulmonary disease care after hospital discharge. Am J Respir Crit Care Med 2022;205(11):1281-1289.
    OpenUrl
  70. 70.↵
    1. Hawthorne G,
    2. Greening N,
    3. Esliger D,
    4. Briggs-Price S,
    5. Richardson M,
    6. Chaplin E,
    7. et al
    . Usability of wearable multiparameter technology to continuously monitor free-living vital signs in people living with chronic obstructive pulmonary disease: prospective observational study. JMIR Hum Factors 2022;9(1):e30091.
    OpenUrl
  71. 71.↵
    1. Zeng S,
    2. Arjomandi M,
    3. Luo G
    . Automatically explaining machine learning predictions on severe chronic obstructive pulmonary disease exacerbations: retrospective cohort study. JMIR Med Inform 2022;10(2):e33043.
    OpenUrl
  72. 72.↵
    1. Pepin JL,
    2. Degano B,
    3. Tamisier R,
    4. Viglino D
    . Remote monitoring for prediction and management of acute exacerbations in chronic obstructive pulmonary disease (AECOPD). Life 2022;12(4):499-508.
    OpenUrl
  73. 73.↵
    1. Konstantinidis A,
    2. Kyriakopoulos C,
    3. Ntritsos G,
    4. Giannakeas N,
    5. Gourgoulianis KI,
    6. Kostikas K,
    7. et al
    . The role of digital tools in the timely diagnosis and prevention of acute exacerbations of COPD: a comprehensive review of the literature. Diagnostics 2022;12(2):269-293.
    OpenUrl
  74. 74.↵
    MagicBand+. Available at: https://disneyworld.disney.go.com/guest-services/magicband-plus/. Accessed February 14, 2023.
  75. 75.↵
    1. Bourbeau J,
    2. Echevarria C
    . Models of care across the continuum of exacerbations with chronic obstructive pulmonary disease. Chron Respir Dis 2020;17.
  76. 76.↵
    1. Mathioudakis AG,
    2. Abroug F,
    3. Agusti A,
    4. Ananth S,
    5. Bakke P,
    6. Bartziokas K,
    7. et al
    . ERS Statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. Eur Respir J 2022;59(5):2102006.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords